Biopharmaceutical company Ipsen (Euronext Paris:IPN) (ADR:IPSEY) announced on Thursday that it has licensed ex-US rights to Day One Biopharmaceuticals' (Nasdaq:DAWN) tovorafenib for paediatric low-grade glioma (pLGG), the most common form of childhood brain cancer.
Tovorafenib is FDA-approved for relapsed or refractory pLGG with BRAF alterations, a condition affecting over half of pLGG cases globally. The drug addresses an unmet need for targeted treatments outside the United States.
Under the agreement Day One will receive USD111m upfront, including USD71m cash and USD40m equity investment, plus up to USD350m in milestones and tiered double-digit royalties.
Ipsen will be responsible for the regulatory and commercial activities for tovorafenib in all territories outside of the United States.
Day One will maintain exclusive global development and US commercial rights for tovorafenib.
Scopio Labs secures fourth FDA clearance
Klotho Neurosciences receives FDA Orphan Drug Designation for ALS gene therapy candidate
Zhimeng Biopharma's CB03-154 ALS Phase 2/3 study receives Chinese clinical trial approval
Taiho Oncology and Taiho Pharmaceutical's INQOVI/venetoclax combination sNDA accepted by US FDA
Alvotech strengthens biosimilar operations with acquisition of Ivers-Lee Group
Adcentrx Therapeutics' ADRX-0405 granted US FDA orphan drug designation
Orsini named KalVista's specialty pharmacy partner for EKTERLY (sebetralstat)
KalVista secures FDA approval for EKTERLY, first oral on-demand HAE treatment
Alcon to acquire LumiThera and its FDA-authorised photobiomodulation device for dry AMD treatment
Akeso's bispecific ADC (Trop2/Nectin4 ADC) enters clinical trials
Biocon Biologics' Denosumab biosimilars receive European Commission approval
Life Molecular Imaging's Neuraceq granted expanded Alzheimer's disease indications by US FDA